MicroRNA-139-5p acts as a suppressor gene for depression by targeting nuclear receptor subfamily 3, group C, member 1.


Journal

Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063

Informations de publication

Date de publication:
05 2022
Historique:
entrez: 11 5 2022
pubmed: 12 5 2022
medline: 14 5 2022
Statut: ppublish

Résumé

MicroRNA-139-5p (miR-139-5p) is one of the most differentially expressed miRNAs in the brain between healthy people and depressed patients. However, its function in depression is unclear. Therefore, we investigated the function of miR-139-5p in depression. Here, miR-139-5p expression was found to be upregulated in the model group. MiR-139-5p inhibition could increase sucrose preference and decrease mice immobility time after chronic corticosterone (CORT) injection. Furthermore, compared with the antago-NC group, 3 weeks of antagomiR-139-5p treatment significantly decreased miR-139-5p level in model group hippocampus, increased sucrose preference index, reduced neuron damages, and enhanced the levels of nuclear receptor subfamily 3 group C member 1 (NR3C1), brain-derived neurotrophic factor (BDNF), phosphorylated/total tyrosine kinase receptor B (p-TrkB/TrkB), phosphorylated/total cAMP-response element-binding protein (p-CREB/CREB) and phosphorylated/total extracellular regulated protein kinases (p-ERK/ERK). Moreover, as a potential target for miR-139-5p, NR3C1 level was reduced by miR-139-5p mimic. Altogether, by activating the BDNF-TrkB signaling pathway, miR-139-5p inhibition plays an antidepressant-like role and might serve as an effective depression target (Fig. graphical abstract).

Identifiants

pubmed: 35543383
doi: 10.1080/21655979.2022.2059937
pmc: PMC9276025
doi:

Substances chimiques

Brain-Derived Neurotrophic Factor 0
MIRN139 microRNA, human 0
MIRN139 microRNA, mouse 0
MicroRNAs 0
Sucrose 57-50-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11856-11866

Références

Ann Transl Med. 2021 Oct;9(20):1594
pubmed: 34790800
PLoS One. 2018 Jun 7;13(6):e0198429
pubmed: 29879167
Science. 2017 Sep 22;357(6357):
pubmed: 28798046
Cell Death Dis. 2018 Jan 5;9(1):3
pubmed: 29305594
Med Sci Sports Exerc. 2019 Jun;51(6):1162-1168
pubmed: 30694979
PLoS One. 2017 Jul 31;12(7):e0181961
pubmed: 28759626
Health Aff (Millwood). 1999 Sep-Oct;18(5):163-71
pubmed: 10495604
Pharmacol Biochem Behav. 2014 May;120:140-8
pubmed: 24631486
J Cell Sci. 2018 Feb 21;131(4):
pubmed: 29467236
Cell Stress Chaperones. 2019 Jul;24(4):719-733
pubmed: 31134533
Oncol Lett. 2017 Aug;14(2):1215-1222
pubmed: 28789336
Biochem Biophys Res Commun. 2017 Mar 25;485(1):167-173
pubmed: 28202414
J Oral Pathol Med. 2018 Mar;47(3):221-227
pubmed: 28650560
Oncotarget. 2017 Jul 11;8(28):46006-46019
pubmed: 28545018
Clin Transl Gastroenterol. 2019 Jan;10(1):e00003
pubmed: 30702491
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):417-425
pubmed: 28764913
Science. 2014 Sep 19;345(6203):1494-8
pubmed: 25237099
Biomark Cancer. 2017 Jan 09;9:1-8
pubmed: 28096697
Bioengineered. 2021 Dec;12(2):11520-11532
pubmed: 34889698
Semin Cancer Biol. 2017 Oct;46:146-157
pubmed: 28185862
Sci Rep. 2017 Jun 29;7(1):4387
pubmed: 28663595
BMC Psychiatry. 2019 Feb 1;19(1):52
pubmed: 30709391
Brain Res Bull. 2021 Apr;169:73-80
pubmed: 33400954
J Biomed Inform. 2019 Jun;94:103180
pubmed: 31039404
Int J Neuropsychopharmacol. 2017 Jun 1;20(6):485-497
pubmed: 28339691
Neurochem Int. 2012 Jun;60(8):743-50
pubmed: 22465943
Neurotox Res. 2018 Oct;34(3):489-510
pubmed: 29736827
Sci Rep. 2017 Mar 06;7:43393
pubmed: 28262692
Evid Based Complement Alternat Med. 2017;2017:7903918
pubmed: 28694833
Clin Epigenetics. 2015 Jul 22;7:69
pubmed: 26199675
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Brain Res. 2014 Aug 19;1577:69-76
pubmed: 24997248
Neuropsychiatr Dis Treat. 2020 Nov 10;16:2689-2693
pubmed: 33204094
Am J Psychiatry. 2018 Apr 1;175(4):327-335
pubmed: 29202655
Neural Plast. 2017;2017:6871089
pubmed: 28246558
Biomed Res Int. 2018 May 20;2018:4149707
pubmed: 29888262
Front Plant Sci. 2017 Nov 21;8:1943
pubmed: 29209340
Oncotarget. 2017 Mar 28;8(13):21187-21199
pubmed: 28177900
Thorac Cancer. 2017 Sep;8(5):461-470
pubmed: 28660665
Neuropsychopharmacology. 2020 May;45(6):1050-1058
pubmed: 31986519
Science. 2017 Feb 10;355(6325):634-637
pubmed: 28183980

Auteurs

Bing Su (B)

Psychology Department, Qingdao Mental Health Center, Qingdao University, Qingdao City, Shandong Province, China.

Suohua Cheng (S)

Psychology Department, Qingdao Mental Health Center, Qingdao University, Qingdao City, Shandong Province, China.

Lei Wang (L)

Psychology Department, Qingdao Mental Health Center, Qingdao University, Qingdao City, Shandong Province, China.

Bing Wang (B)

Pharmacy Department, Qingdao Women and Children's Hospital, Qingdao City, Shandong Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH